Published in Br J Cancer on February 14, 2005
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol (2009) 1.23
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res (2013) 1.06
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer (2006) 1.06
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer (2010) 0.98
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin Cancer Res (2008) 0.92
Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer (2008) 0.92
Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res (2011) 0.91
A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers. Cell Death Dis (2013) 0.85
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells. J Cancer Res Clin Oncol (2009) 0.84
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer (2012) 0.84
Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol Cancer (2006) 0.83
Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1. J Control Release (2012) 0.81
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer (2012) 0.77
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
The biochemistry of apoptosis. Nature (2000) 18.91
Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res (2003) 7.15
Bioanalytical method validation--a revisit with a decade of progress. Pharm Res (2000) 6.83
The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene (1998) 3.98
Characterization of XIAP-deficient mice. Mol Cell Biol (2001) 3.32
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol (1999) 3.28
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell (2004) 3.14
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 2.71
XIAP: apoptotic brake and promising therapeutic target. Apoptosis (2001) 2.28
Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res (2003) 1.83
XIAP, the guardian angel. Nat Rev Mol Cell Biol (2001) 1.72
Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68
Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci (2002) 1.53
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 1.47
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res (2003) 1.39
High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res (2004) 1.36
Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics (2000) 1.33
Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res (2001) 1.32
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res (2001) 1.30
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis (2003) 1.30
Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther (2002) 1.26
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des (2003) 1.24
Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer (2003) 1.24
XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol (2004) 1.16
Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol (2002) 1.15
Expression of a cytokeratin 18 neo-epitope is a specific marker for trophoblast apoptosis in human placenta. Placenta (2001) 1.09
XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med (2003) 1.07
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res (2002) 1.06
Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer (2004) 1.04
Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer (2003) 1.01
Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res (2003) 0.98
Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med (2003) 0.97
Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol (2003) 0.95
Apoptosis induced by low-dose and low-dose-rate radiation. Cancer (2002) 0.92
M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med (2000) 0.89
Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers? Cancer Cell (2004) 0.89
An immunohistochemical study of the clearance of apoptotic cellular fragments. Cell Mol Life Sci (2002) 0.88
Analytical validation of a real-time reverse transcription-polymerase chain reaction quantitation of different transcripts of the Wilms' tumor suppressor gene (WT1). Anal Biochem (2002) 0.83
Immunohistochemical detection of cytokeratin 18 and its neo-epitope in human salivary glands and pleomorphic adenomas. Anticancer Res (2000) 0.80
Identifying relevant studies for systematic reviews. BMJ (1994) 12.21
The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell (1995) 5.50
Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 4.84
Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature (1996) 4.55
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J (1993) 3.75
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol (1999) 3.18
Handsearching versus electronic searching to identify reports of randomized trials. Cochrane Database Syst Rev (2007) 2.91
A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol (1999) 2.84
IgA subclasses in various secretions and in serum. Immunology (1982) 2.43
Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol (2008) 2.28
Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev (2002) 2.15
Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem (2009) 2.09
An investigation of the adequacy of MEDLINE searches for randomized controlled trials (RCTs) of the effects of mental health care. Psychol Med (1994) 2.08
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93
Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J Clin Invest (1983) 1.86
Asymmetric division in mouse oocytes: with or without Mos. Curr Biol (2000) 1.84
Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J Clin Invest (1982) 1.84
'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods (2009) 1.81
Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci (1996) 1.80
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst (2000) 1.77
Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology (2006) 1.77
Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev (2004) 1.74
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus (1995) 1.63
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Nature and origin of the proteins of bile. I. A comparative analysis of serum and bile proteins in man. Eur J Clin Invest (1974) 1.59
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res (1993) 1.59
Identification of a minimal hydrophobic domain in the herpes simplex virus type 1 scaffolding protein which is required for interaction with the major capsid protein. J Virol (1996) 1.56
Childhood lead poisoning and vinyl miniblind exposure. Arch Pediatr Adolesc Med (1997) 1.52
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer (2009) 1.50
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Apoptosis and cancer chemotherapy. Trends Cell Biol (2001) 1.48
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer (2004) 1.45
Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest (1984) 1.44
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Transport of animals. Vet Rec (1995) 1.39
Origin and nature of the proteins of bile. II. A comparative analysis of serum, hepatic lymph and bile proteins in the dog. Eur J Clin Invest (1974) 1.38
Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci (1990) 1.34
Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J (2001) 1.32
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol (2001) 1.32
Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol (2008) 1.32
A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials. Stat Med (2002) 1.31
Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death. Cell Death Differ (2003) 1.27
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene (2008) 1.26
Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med (1997) 1.24
Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol (1999) 1.24
Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. Oncogene (2001) 1.23
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci (1996) 1.20
Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res (1993) 1.20
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol (2007) 1.19
DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev (2004) 1.19
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer (2006) 1.18
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene (2009) 1.17
Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol (1998) 1.17
Mos activates MAP kinase in mouse oocytes through two opposite pathways. EMBO J (2000) 1.16
Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Am J Physiol (1996) 1.15
Bid, a widely expressed proapoptotic protein of the Bcl-2 family, displays lipid transfer activity. Mol Cell Biol (2001) 1.13
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer (2012) 1.11
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3. J Virol (2000) 1.10
Genomic characterization of the mouse inhibitor of apoptosis protein 1 and 2 genes. Genomics (1997) 1.08
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer (2010) 1.08
Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology (1991) 1.07
Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol (1997) 1.07
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer (2000) 1.07
Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol Cell Biol (1998) 1.06
Evaluation of Toll-like receptor and adaptor molecule polymorphisms for susceptibility to tuberculosis in a Colombian population. Int J Immunogenet (2012) 1.05
The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta (1997) 1.05
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05
Hypoxia in head and neck cancer. Br J Radiol (2006) 1.04
Age and ceftriaxone kinetics. Clin Pharmacol Ther (1984) 1.04
Dynamic CT in pancreatic lymphoma. J Comput Assist Tomogr (1993) 1.04
Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg (1995) 1.04
VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer (1995) 1.04
Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol (1996) 1.03
Self-reported and measured weights and heights of participants in community-based weight loss programs. J Am Diet Assoc (1992) 1.02
Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases. Dig Dis Sci (1982) 1.02
The liver in the IgA secretory immune system. Dogs, but not rats and rabbits, are suitable models for human studies. Hepatology (1983) 1.01
Biomarkers of apoptosis. Br J Cancer (2008) 1.01
Hepatic abscess likely related to Leptotrichia buccalis in an immunocompetent patient. Liver (1996) 1.01
Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med (1999) 1.01
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer (2011) 1.00
Jejunal immunoglobulin and antigliadin antibody secretion in adult coeliac disease. Gut (1990) 1.00
Virus-specific interaction between the human cytomegalovirus major capsid protein and the C terminus of the assembly protein precursor. J Virol (1996) 1.00